GENA-111-AF / Genome & Company, Debiopharm - LARVOL DELTA

Genome & Company licenses out ADC to Swiss firm Debiopharm (Korea Biomedical Review) - "Genome & Company, a Korean new drug developer, said on Monday that it signed a $426 million deal with Debiopharm, a Switzerland-based pharmaceutical company, to license out GENA-111, an antibody-drug conjugate (ADC)...The deal includes an upfront payment of $5 million, milestone payments, and royalties based on net sales....GENA-111 targets CD239, a novel target discovered through Genome & Company's drug discovery platform Gnocle."

Licensing / partnership • Oncology • Solid Tumor

Genome & Company, breaking away from the microbiome 'one tool'… 'Technology transfer of anti-cancer drugs within the year' [Google translation] (HIT News) - "Genome & Company plans to transfer technology within the year for new target anticancer drugs...The pipelines announced for technology transfer within the year at the meeting were 'GENA-104 (development code name)' and 'GENA-111'...CEO Bae explained that he is currently discussing a specific term sheet with global pharmaceutical companies for the pipeline....Based on the results of confirming the possibility of such development, the company predicted that it would submit a phase 1 clinical trial plan (IND) for GENA-104 within the third quarter."

Commercial • IND • New P1 trial • Oncology • Solid Tumor

The antibody-drug conjugate GENA-111 conjugated to auristatin F shows therapeutic potency in BCAM positive epithelial cancer (AACR 2022) - "The results of this study will be presented and discussed. Taken together, our data suggest that an ADC targeting BCAM e.g., GENA-111-auristatin F, might be a promising treatment strategy for BCAM positive epithelial cancer patients."

Oncology • Skin Cancer • CTSB